ImmuneFx Personalized Immunotherapy Platform
While most immunotherapies focus on a single aspect of cancer immunity, ImmuneFx modulates the tumor microenvironment in multiple ways by priming, generating, guiding and augmenting both innate and adaptive immune pathways.
________________________________________________________________________
- Off-the-shelf products induce personalized anti-tumor effect in situ
- Requires no patient information for manufacturing
- Requires no patient information for effectiveness
- Robust, comprehensive polyvalent immune response
- Multiple types of immune cells (innate and adaptive) in inflamed tumor microenvironment
- Systemic response to multiple tumor antigens through optimal antigen presentation/T cell priming and epitope spreading
- Automatically educates naïve T cells to their cognate neoantigens
- Leverages mutational load to take advantage of maximum number of tumor antigen targets
- Broadly applicable to all solid tumors/lymphomas
- No possibility of viral recombination or systemic infection by live viruses or bacteria
- Multiple delivery options
- Tested in multiple naturally occurring cancers in multiple large animal species
- No product-related serious adverse events in preclinical studies and clinical trials demonstrated
- Products can be produced quickly and at very low cost compared to other therapies
TME=tumor microenvironment; APCs=antigen presenting cells
Murine Neuroblastoma Pre-clinical Study
Canine B Cell Lymphoma Nonclinical Study
Canine B Cell Lymphoma Nonclinical Study
- Strong humoral & cell-mediated responses
- Prevented tumor formation in 100% of mice and increased survival in challenged mice by 81% (N=259)
- Increased long-term survival by 88%
- Promoted massive infiltration of lymphocytes
- Dose-dependent therapeutic effect
- No Adverse Events or Serious Adverse Events
__________________________________________________
Canine B Cell Lymphoma Nonclinical Study
Canine B Cell Lymphoma Nonclinical Study
Canine B Cell Lymphoma Nonclinical Study
- Enhanced survival:
- Untreated (historical) 7-59 days
- Standard-of-care (historical) = 183-365 days
- IFx-CL alone (N=17)
- Median survival time: 123 days
- IFx-CL + Standard-of-care (N = 10)
- Median ongoing survival: 389 days
- Strong humoral & cell-mediated responses
- No Adverse Events or Serious Adverse Events
__________________________________________________
Equine Melanoma USDA Field Study
Murine Melanoma Pre-clinical Study
Murine Melanoma Pre-clinical Study
- Response: % change in total (injected/noninjected) tumor burden (RECIST v1.1/VCOG) between weeks 1-35 (N=22)
- PD = 0/22 = 0%
- PR = 6/22 = 27%
- SD = 16/22= 73%
- Tumor regression = 17/22 = 77%
- Humoral & CD4+ & CD8+ cellular responses
- No Adverse Events or Serious Adverse Events
___________________________________________________
Murine Melanoma Pre-clinical Study
Murine Melanoma Pre-clinical Study
Murine Melanoma Pre-clinical Study
- Strong humoral & cell-mediated responses
- pAc/emm55 plus anti-PD-1 Antibody delayed tumor growth & increased survival (N=257)
- INF-ϒ production by dendritic cells
- Enhanced CD4+/CD8+ T cell tumor infiltration
- Systemic immune response dependent on both CD4+/CD8+
- No Adverse Events or Serious Adverse Events
___________________________________________________
ImmuneFx has the potential to broaden the applicability of checkpoint blockades by priming robust, patient-specific, multivalent responses in naïve, unresponsive, or refractory patients